한스바이오메드
Financials
Valuation Metrics
한스바이오메드's Market Cap is ₩2888B. At end of 2025 it was ₩3936B. Ranked #669 of 2,436 in KR market (top 27%), #270 of 1,649 on KOSDAQ (top 16%), #76 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 32%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 288.79B KRW | KR#669/2,436 Sec#76/234 |
| Revenue | 89.78B KRW | KR#1,459/2,436 Sec#92/234 |
| Net Income | -32.08B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 126.41B KRW | KR#1,585/2,436 Sec#127/234 |
| Net Assets | 33.89B KRW | KR#2,121/2,436 Sec#186/234 |
| Employees | 247 | KR#928/2,436 Sec#80/234 |
| Value | ||
| P/B | 8.52x | KR#2,328/2,436 Sec#206/234 |
| P/S | 3.22x | KR#2,022/2,436 Sec#128/234 |
| FCF Yield | -0.48% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -94.65% | KR#2,337/2,436 Sec#218/234 |
| ROA | -25.37% | KR#2,260/2,436 Sec#186/234 |
| Op. Margin | -28.84% | KR#2,176/2,436 Sec#152/234 |
| Revenue Growth | 10.65% | KR#898/2,436 Sec#81/234 |
| Financial Health | ||
| Debt Ratio | 373.03% | KR#2,235/2,436 Sec#224/234 |
| Total Debt | 76.60B KRW | KR#813/2,436 Sec#57/234 |
| FCF | -1.38B KRW | KR#1,301/2,436 Sec#100/234 |
| Cash | 8.15B KRW | KR#1,789/2,436 Sec#152/234 |
| Current Ratio | 0.69x | KR#2,133/2,436 Sec#203/234 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | 147.25% | KR#78/2,436 Sec#4/234 |
| 1M Return | -12.15% | KR#2,072/2,436 Sec#195/234 |
| From 52W High | -64.97% | KR#1,965/2,436 Sec#169/234 |
| 1Y MDD | -68.92% | KR#1,901/2,436 Sec#161/234 |
| Trading | ||
| Volume | 128,524 shares | KR#951/2,436 Sec#84/234 |
| Foreign Own. | 7.10% | KR#613/2,436 Sec#58/234 |
| Per Share | ||
| EPS | -1,807 KRW | KR—/2,436 Sec—/234 |
| BPS | 5,204 KRW | KR#1,406/2,436 Sec#102/234 |
Company Info
Established in 1999, this company manufactures and sells human implantable skin, bone graft materials, and medical devices, having been listed on KOSDAQ in 2009. It is the first bio-company in Asia to successfully commercialize human skin, bone, and silicone implant products, receiving South Korea's first human tissue bank establishment license from the Ministry of Food and Drug Safety. The company is expanding its global business through overseas subsidiaries in the United States, Thailand, and the United Kingdom, and continuously increases R&D investments in new medical technology fields such as tissue engineering and vascular hemostatic devices. HansBiomed was established in 1999 and is headquartered in Songpa-gu, Seoul Metropolitan City.